



FOR: CARDIOCOMM SOLUTIONS, INC.
TSX VENTURE SYMBOL: EKG

May 15, 2019

CARDIOCOMM SOLUTIONS ANNOUNCES ECG SERVICES INTEGRATION AND CO-MARKETING AGREEMENT WITH CALIFORNIA-BASED BODIMETRICS LLC

Integration of GEMS™ Universal ECG App with BodiMetrics hardware platform expands ECG Device Manufacturer's Offerings to now Include Credible ECG Reporting Services

TORONTO, ONTARIO - CardioComm Solutions, Inc. (TSX VENTURE:EKG) ("**CardioComm**" or the "**Company**"), a global provider of consumer heart monitoring and electrocardiogram ("**ECG**") acquisition and management software solutions, announces the execution of an ECG and multiple biosign monitoring device integration and co-marketing agreement with California-based BodiMetrics LLC ("**BodiMetrics**").

With the launch of CardioComm's GEMS™ Universal ECG app ("**GEMS™ Universal**"), BodiMetrics users can now benefit from access to CardioComm's trusted ECG report generation and reporting capabilities. BodiMetrics will promote the use of GEMS™ Universal to its extensive customer base and CardioComm will share resultant revenues generated from GEMS™ Universal subscription fees and from paid-for ECG readings. Under the agreement, CardioComm also has distribution rights for the sale of devices through its hospital, telemedicine and consumer sales channels.

GEMS™ Universal will be available under two subscription models:




GEMS™ Universal ECG

- \$6 US per month with one free ECG interpretation included; and,
- \$69 US per year with 12 free ECG interpretations that may be requested any time during the one year subscription.

GEMS™ Universal is based directly on the Company's GEMS™ Mobile ECG and was developed to allow non-HeartCheck™ branded ECG devices users to generate unlimited, medical-grade ECG PDFs or to request a review of their ECG(s) through CardioComm's SMART Monitoring ECG reading service on a fee-for-review basis. Once the free ECG reviews have been used, additional SMART Monitoring reviews can be requested for \$1.99 US for an ECG triage or \$12.50 US for a physician interpretation.

The BodiMetrics device replaces five (5) devices with one: ECG, Heart Rate, Systolic Blood Pressure, Blood Oxygenation (Spo2%) and Temperature. BodiMetrics confirms that approximately 30,000 devices have been sold to date with annual sales volumes increasing 50% to 60% each year. US sales occur through Amazon, Best Buy, Costco and various e-commerce channels. Additional sales occur through medical device distributors, Medline, Henry Schein, employer care management partners and telemedicine, patient and virtual care platforms.



A second phase of the agreement will see the GEMS™ Mobile's ECG management technology embedded directly into BodiMetrics' device app under a licensing agreement, allowing the user to open only one app to access all existing biometric use options as well as ECG monitoring. Additional information will be provided when the ECG enabled BodiMetrics app is released later this year.

The Company reported the launch of the GEMS™ Universal ECG app on May 14, 2019. The app is now available on Google Play and is scheduled to be available on the App Store within two weeks.

For further updates regarding GEMS™ Mobile ECG device partnerships please see the Companies websites at www.bodimetrics.com, www.theheartcheck.com and www.cardiocommsolutions.com.



About CardioComm Solutions

CardioComm Solutions' patented and proprietary technology is used in products for recording, viewing, analyzing and storing electrocardiograms for diagnosis and management of cardiac patients. Products are sold worldwide through a combination of an external distribution network and a North American-based sales team. CardioComm Solutions has earned the ISO 13485 certification, is HIPAA compliant and holds clearances from the European Union (CE Mark), the USA (FDA) and Canada (Health Canada).

FOR FURTHER INFORMATION PLEASE CONTACT:

Etienne Grima, Chief Executive Officer

1-877-977-9425 x227

egrima@cardiocommsolutions.com

investor.relations@cardiocommsolutions.com

Forward-looking statements

This release may contain certain forward-looking statements and forward-looking information with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. Such statements and information reflect management's current beliefs and are based on information currently available to management. By their nature, forward-looking statements and forward-looking information involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements and forward-looking information.

In evaluating these statements, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not assume any obligation to update the forward-looking statements and forward-looking information contained in this release other than as required by applicable laws, including without limitation, Section 5.8(2) of National Instrument 51-102 (*Continuous Disclosure Obligations*).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.